Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

166624

	registered interest
	date	27/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pancreatic Cancer: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what discussions they have had with NHS England regarding unmet need in respect of pancreatic cancer treatment when re-evaluating medicines on the Cancer Drugs Fund list.
	tabling member printed	Baroness Masham of Ilton
	uin	HL3215
	answer	answer is ministerial correction date of answer 04/12/2014 answer text <p>We have had no such discussions. These are matters for NHS England’s Cancer Drugs Fund clinical panel.</p><p> </p><p><br> The panel plans to meet on 15 and 16 December to assess, on the basis of the latest evidence, whether certain drugs should continue to be made routinely available to new patients through the Fund and to consider a number of new drugs for potential addition to the Fund.</p><p> </p><p> </p><p> </p><p>In making such decisions, the panel will take into account a number of factors, including unmet need.</p><p> </p><p><br> NHS England has assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.</p><p> </p> answering member printed Earl Howe grouped question UIN HL3216 question first answered 04/12/2014 16:06:53 answering member 2000 label Biography information for Earl Howe
	tabling member	1850 label Biography information for Baroness Masham of Ilton

166625

	registered interest
	date	27/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pancreatic Cancer: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what discussions they have had with NHS England regarding innovation in pancreatic cancer treatment when assessing medicines for inclusion on the Cancer Drugs Fund list.
	tabling member printed	Baroness Masham of Ilton
	uin	HL3216
	answer	answer is ministerial correction date of answer 04/12/2014 answer text <p>We have had no such discussions. These are matters for NHS England’s Cancer Drugs Fund clinical panel.</p><p> </p><p><br> The panel plans to meet on 15 and 16 December to assess, on the basis of the latest evidence, whether certain drugs should continue to be made routinely available to new patients through the Fund and to consider a number of new drugs for potential addition to the Fund.</p><p> </p><p> </p><p> </p><p>In making such decisions, the panel will take into account a number of factors, including unmet need.</p><p> </p><p><br> NHS England has assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.</p><p> </p> answering member printed Earl Howe grouped question UIN HL3215 question first answered 04/12/2014 16:06:53 answering member 2000 label Biography information for Earl Howe
	tabling member	1850 label Biography information for Baroness Masham of Ilton

166612

	registered interest
	date	27/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ambulance Services: City of Westminster
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what is their assessment of the current London Ambulance Service response times to life-threatening incidents (category A calls) within the City of Westminster.
	tabling member printed	Lord Hoyle
	uin	HL3203
	answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>The performance standard for ambulance trusts responding to Category A calls is that an ambulance resource should arrive within eight minutes of the call 75% of the time.</p><p> </p><p> </p><p> </p><p>We understand that this year to date (1 April 2014 -28 November 2014) the London Ambulance Service has achieved a response rate to ‘category A’ calls in Westminster of 69.58%.</p><p> </p><p> </p><p> </p><p>We are providing extra support to the National Health Service – including £50 million to help ambulance trusts with additional demand and help them to return to meeting the standard as quickly as possible.</p><p> </p> answering member printed Earl Howe question first answered 05/12/2014 14:26:08 answering member 2000 label Biography information for Earl Howe
	tabling member	1000 label Biography information for Lord Hoyle

166637

	registered interest
	date	27/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	IVF
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government when they intend to bring forward regulations which will permit the implantation of embryos free of harmful mitochondrial mutations into the uterus of women carrying such harmful mutations.
	tabling member printed	Lord Walton of Detchant
	uin	HL3228
	answer	answer is ministerial correction date of answer 04/12/2014 answer text <p>The Government will update Parliament as soon as possible with regard to these regulations.</p><p> </p> answering member printed Earl Howe question first answered 04/12/2014 15:48:52 answering member 2000 label Biography information for Earl Howe
	tabling member	1716 label Biography information for Lord Walton of Detchant

166622

	registered interest
	date	27/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pancreatic Cancer: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government, in the light of the proposed re-evaluation of treatments on the Cancer Drugs Fund list, what assurances they can provide to patients with pancreatic cancer that the latest medicines will continue to be made available to them on the National Health Service.
	tabling member printed	Baroness Masham of Ilton
	uin	HL3213
	answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>The Government is committed to ensuring that patients have access to effective treatments, including those for pancreatic cancer, on terms that represent value to the National Health Service and the taxpayer.</p><p> </p><p> </p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing advice to the NHS on the clinical and cost-effectiveness of health technologies.</p><p> </p><p> </p><p> </p><p>NICE has recommended gemcitabine as a treatment option for pancreatic cancer in technology appraisal guidance published in May 2001, subject to certain clinical criteria, and has been asked to appraise a number of other pancreatic cancer drugs. NHS commissioners are legally required to fund treatments recommended by NICE technology appraisal guidance.</p><p> </p><p><em> </em></p><p> </p><p>Where a pancreatic cancer drug is not routinely available on the NHS, patients may be able to access it through the Cancer Drugs Fund.</p><p> </p><p><br> NHS England’s Cancer Drugs Fund panel plans to assess, on the basis of the latest evidence, whether certain drugs, including Abraxane (albumin bound paclitaxel) for advanced pancreatic cancer, should continue to be made routinely available to new patients through the Fund and to consider a number of new drugs for potential addition to the Fund.</p><p> </p><p> </p><p> </p><p>NHS England has assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.<br> <br> We are committed to maintaining the Cancer Drugs Fund until the end of March 2016. We will carefully consider with NHS England what arrangements should be put in place for the long term.</p><p> </p><p> </p><p> </p><p>Surgery, radiotherapy and chemotherapy treatments that may be used for pancreatic cancer are commissioned by NHS England. NHS England’s pancreatic cancer service specification clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services.</p><p> </p><p><br> NHS England has also committed to make up to £6 million available over the next three years to support six trials by Cancer Research UK - one of which will be on pancreatic cancer - into the use of Stereotactic Ablative Radiotherapy (SABR), an innovative radiotherapy treatment. This will allow patients to receive SABR treatment where clinicians think they could benefit. At the same time doctors can fully assess the effectiveness of this treatment so that, if it proves to be effective, it will be available for patients on the NHS where appropriate.</p><p> </p><p> </p><p> </p><p>We are also commissioning an external review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.</p><p> </p> answering member printed Earl Howe question first answered 05/12/2014 14:28:28 answering member 2000 label Biography information for Earl Howe
	tabling member	1850 label Biography information for Baroness Masham of Ilton

166623

	registered interest
	date	27/11/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Pancreatic Cancer: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what action they are taking to ensure that all treatments for advanced pancreatic cancer shown to be effective are made available to patients on the National Health Service.
	tabling member printed	Baroness Masham of Ilton
	uin	HL3214
	answer	answer is ministerial correction date of answer 05/12/2014 answer text <p>The Government is committed to ensuring that patients have access to effective treatments, including those for pancreatic cancer, on terms that represent value to the National Health Service and the taxpayer.</p><p> </p><p> </p><p> </p><p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing advice to the NHS on the clinical and cost-effectiveness of health technologies.</p><p> </p><p> </p><p> </p><p>NICE has recommended gemcitabine as a treatment option for pancreatic cancer in technology appraisal guidance published in May 2001, subject to certain clinical criteria, and has been asked to appraise a number of other pancreatic cancer drugs. NHS commissioners are legally required to fund treatments recommended by NICE technology appraisal guidance.</p><p> </p><p><em> </em></p><p> </p><p>Where a pancreatic cancer drug is not routinely available on the NHS, patients may be able to access it through the Cancer Drugs Fund.</p><p> </p><p><br> NHS England’s Cancer Drugs Fund panel plans to assess, on the basis of the latest evidence, whether certain drugs, including Abraxane (albumin bound paclitaxel) for advanced pancreatic cancer, should continue to be made routinely available to new patients through the Fund and to consider a number of new drugs for potential addition to the Fund.</p><p> </p><p> </p><p> </p><p>NHS England has assured the Department that no patient whose treatment is currently being funded through the Fund will have funding withdrawn, as long as it is clinically appropriate that they continue to receive that treatment. In addition, no drug will be removed from the Fund where it is the only therapy for that condition.<br> <br> We are committed to maintaining the Cancer Drugs Fund until the end of March 2016. We will carefully consider with NHS England what arrangements should be put in place for the long term.</p><p> </p><p> </p><p> </p><p>Surgery, radiotherapy and chemotherapy treatments that may be used for pancreatic cancer are commissioned by NHS England. NHS England’s pancreatic cancer service specification clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services.</p><p> </p><p><br> NHS England has also committed to make up to £6 million available over the next three years to support six trials by Cancer Research UK - one of which will be on pancreatic cancer - into the use of Stereotactic Ablative Radiotherapy (SABR), an innovative radiotherapy treatment. This will allow patients to receive SABR treatment where clinicians think they could benefit. At the same time doctors can fully assess the effectiveness of this treatment so that, if it proves to be effective, it will be available for patients on the NHS where appropriate.</p><p> </p><p> </p><p> </p><p>We are also commissioning an external review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.</p><p> </p> answering member printed Earl Howe question first answered 05/12/2014 14:29:26 answering member 2000 label Biography information for Earl Howe
	tabling member	1850 label Biography information for Baroness Masham of Ilton